Business Atlas

How Enterprise Is Built
Sign In
Text size
100%
Theme
Companies and Brands

Viatris Inc.

Health Care

Viatris Inc. is an American pharmaceutical company headquartered in Canonsburg, Pennsylvania, one of the largest producers of generic and off-patent branded medicines in the world. It was formed in November 2020 through the merger of Mylan N.V., itself a longstanding major generic drug manufacturer, with Upjohn, the off-patent branded medicines business that Pfizer spun off as part of the deal. Viatris manufactures and sells a very broad portfolio of generic and established branded prescription drugs across many therapeutic areas, and the company positions itself around expanding access to medicine by supplying lower-cost versions of treatments after their original patent protection has expired.

Facts
Company Type
Public 1
Founded Year
2020 1
Headquarters
Canonsburg, Pennsylvania, U.S. 1
Size Band
10,000 to 99,999 2
Listing
Nasdaq 3
Status
Active 3
Company Type
Company Type (category)
Public 1
Connections

Operates In

Source Wikidata: Viatris Inc.
In the Other Atlases

Located In

Also in Geography Atlas: where this subject is located.

Sources
1. Wikipedia: Viatris
  • Lead section
    The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
  • Infobox, type
    Public
  • Infobox, hq_location_city
    Canonsburg, Pennsylvania
View the Source
2. StockAnalysis.com: StockAnalysis company profile for Viatris Inc.
StockAnalysis.comCompany profile: Employees
Quote, Company profile: Employees
Employees 30,000
View the Source
3. U.S. Securities and Exchange Commission (EDGAR): SEC EDGAR submissions for Viatris Inc
U.S. Securities and Exchange Commission (EDGAR)
  • exchanges
    "exchanges": [ "Nasdaq" ]
  • tickers
    "tickers": [ "VTRS" ]
View the Source
Wikidata: Viatris Inc.
  • Wikidata Q101983981, class allow-list match (w-wdresolver-0926)
  • Operates In: Pharmaceutical Industry, Wikidata Q101983981
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.